Lunai Bioworks EPS LNAI
Diluted earnings per share by quarter and over the last twelve months, from 2011.
- Last 12 months, to Mar 31, 2026
- −$58.00
- Latest quarter, Q3 FY26
- −$0.80
- Fiscal year 2025
- −$83.28
Lunai Bioworks' earnings per share was −$58.00 over the twelve months to Mar 31, 2026.
In its latest quarter, Q3 FY26, it was −$0.80.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$83.28 | n/a |
| FY2024 | −$68.00 | n/a |
| FY2023 | −$56.00 | n/a |
| FY2022 | −$172.00 | n/a |
| FY2021 | −$44.80 | n/a |
| FY2020 | −$20.00 | n/a |
| FY2019 | −$40.00 | n/a |
| FY2018 | −$28.80 | n/a |
| FY2017 | −$17.60 | n/a |
| FY2016 | −$14.40 | n/a |
| FY2015 | −$36.80 | n/a |
| FY2014 | −$24.00 | n/a |
| FY2013 | −$6.40 | n/a |
| FY2012 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | −$0.80 | n/a | −$58.00 | |
| Q2 FY26 | −$0.64 | n/a | −$57.20 | |
| Q1 FY26 | $1.04 | n/a | −$60.16 | |
| Q4 FY25 | −$57.60 | n/a | −$83.28 | |
| Q3 FY25 | $0.00 | n/a | −$33.68 | |
| Q2 FY25 | −$3.60 | n/a | −$76.88 | |
| Q1 FY25 | −$22.08 | n/a | −$78.88 | |
| Q4 FY24 | −$8.00 | n/a | −$68.00 | |
| Q3 FY24 | −$43.20 | n/a | −$92.00 | |
| Q2 FY24 | −$5.60 | n/a | −$55.20 | |
| Q1 FY24 | −$11.20 | n/a | −$56.00 | |
| Q4 FY23 | −$32.00 | n/a | −$56.00 |
Against its peers
Companies in Healthcare nearest Lunai Bioworks' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| LNAILunai Bioworks | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $0.02 | |
| EDUCEducational Development | $0.19 | |
| GTIMGood Times Restaurants | $0.21 | +75% a year |
| Peer median | $0.19 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Lunai Bioworks
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.